A Study of E7389 Liposomal Formulation (E7389-LF) Plus Nivolumab in Participants With Solid Tumor

NCT04078295 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

125

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Neoplasms

Interventions

DRUG: E7389-LF
DRUG: Nivolumab

Sponsor

Eisai Co., Ltd.

Collaborators

[object Object]